Emergent BioSolutions (FRA:ER4) Loans Receivable: €0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ER4 Emergent BioSolutions Inc FRA:ER4
61 GF Score
Price €6.54
GF Value €4.15
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Emergent BioSolutions Loans Receivable?

Emergent BioSolutions FRA:ER4 +2.19% 61 Loans Receivable is €0.0 Mil as of Jun. 2026. GuruFocus rates FRA:ER4 with a GF Score™ of 61/100 and a GF Value™ of €4.15 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Emergent BioSolutions's Loans Receivable for the quarter that ended in Jun. 2026 was €0.0 Mil.

Emergent BioSolutions Loans Receivable Related Terms

Emergent BioSolutions Loans Receivable Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions Loans Receivable Chart

Emergent BioSolutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Emergent BioSolutions Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:ER4
61GF Score
Emergent BioSolutions Inc FRA:ER4
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emergent BioSolutions Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0.0 Mil mean?
Emergent BioSolutions (FRA:ER4) has a Loans Receivable of €0.0 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Loans Receivable too high?
Emergent BioSolutions' current Loans Receivable is €0.0 Mil. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Loans Receivable compare to EOLS and ELTP?
Emergent BioSolutions' Loans Receivable of €0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Emergent BioSolutions and its competitors. Emergent BioSolutions's current Loans Receivable is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (FRA:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.15, compared to a current price of €6.54 — trading 57.5% above its estimated fair value. The current Loans Receivable is €0.0 Mil. Emergent BioSolutions' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Emergent BioSolutions (FRA:ER4), the current Loans Receivable is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (FRA:ER4) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of €6.54 is trading 57.5% above its estimated GF Value™ of €4.15. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for FRA:ER4:

  • Loans Receivable: €0.0 Mil
  • GF Value™: €4.15 vs. price of €6.54 (57.5% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the FRA:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Emergent BioSolutions Business Description

Other Exchanges EBS:USA0IGA:UKER4:Germany
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score

Get the complete analysis for FRA:ER4

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.54
Price
€4.15
GF Value